Análisis de la acción DaVita Inc (DVA)DVADaVita Inc

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company's robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company's international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company's U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

DaVita Inc is a good buy right now due to its strong earnings growth, with an EPS of $4.02 in Q2 reflecting a 55% year-over-year increase, and a forward P/E ratio of 9.95, which is attractive compared to industry averages. The stock is currently priced at $183.64, significantly below Deutsche Bank's target of $265, indicating substantial upside potential. However, the main risk is the recent insider selling trend, with Berkshire Hathaway reducing its holdings by approximately 1.6 million shares, which could signal caution among large investors.

13 analysts cover DVA: 3 rate it Buy, 8 Hold and 2 Sell. The average price target is 162.50.